Paul Grof Selected Research

Lithium

7/2022	Correction: Combining schizophrenia and depression polygenic risk scores improves the genetic prediction of lithium response in bipolar disorder patients.
2/2022	Using polygenic scores and clinical data for bipolar disorder patient stratification and lithium response prediction: machine learning approach.
1/2022	Using polygenic scores and clinical data for bipolar disorder patient stratification and lithium response prediction: machine learning approach - CORRIGENDUM.
11/2021	Combining schizophrenia and depression polygenic risk scores improves the genetic prediction of lithium response in bipolar disorder patients.
11/2021	Exemplar scoring identifies genetically separable phenotypes of lithium responsive bipolar disorder.
1/2021	Association of polygenic score for major depression with response to lithium in patients with bipolar disorder.
1/2021	HLA-DRB1 and HLA-DQB1 genetic diversity modulates response to lithium in bipolar affective disorders.
7/2019	Clinical use of lithium salts: guide for users and prescribers.
1/2019	The Emergent Course of Bipolar Disorder: Observations Over Two Decades From the Canadian High-Risk Offspring Cohort.
9/2018	Lithium Treatment in Children and Adolescents.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Paul Grof Research Topics

Disease

42	Bipolar Disorder (Manic Depressive Psychosis) 07/2022 - 10/2002
12	Mood Disorders (Mood Disorder) 01/2021 - 10/2002
5	Schizophrenia (Dementia Praecox) 07/2022 - 10/2002
4	Disease Progression 01/2013 - 12/2002
3	Mental Disorders (Mental Disorder) 03/2021 - 10/2004
2	Genetic Risk Score 07/2022 - 11/2021
2	Mania (Manias) 09/2018 - 01/2005
2	Anxiety Disorders (Anxiety Disorder) 01/2010 - 12/2007
1	Weight Gain 09/2018
1	Inflammation (Inflammations) 01/2018
1	Psychotic Disorders (Schizoaffective Disorder) 02/2014
1	Major Affective Disorder 2 01/2013
1	Body Weight (Weight, Body) 11/2012
1	Frailty 06/2010
1	Depressive Disorder (Melancholia) 01/2010
1	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 12/2007
1	Cognitive Dysfunction 10/2004

Drug/Important Bio-Agent (IBA)

36	LithiumIBA 07/2022 - 10/2002
4	Pharmaceutical PreparationsIBA 01/2021 - 10/2002
3	Antipsychotic Agents (Antipsychotics)IBA 03/2021 - 06/2007
3	Hydrocortisone (Cortisol)FDA LinkGeneric 12/2016 - 08/2003
3	Antidepressive Agents (Antidepressants)IBA 01/2013 - 01/2005
2	Drug CombinationsIBA 01/2013 - 01/2003
2	Environmental BiomarkersIBA 12/2012 - 05/2012
1	Prescription DrugsIBA 03/2021
1	HLA-DQB1 antigen (HLA DQB1)IBA 01/2021
1	HLA-DRB1 Chains (HLA DRB1)IBA 01/2021
1	SaltsIBA 07/2019
1	Neuroprotective AgentsIBA 09/2018
1	Risperidone (Risperdal Consta)FDA LinkGeneric 09/2018
1	ProlactinIBA 09/2018
1	MicroRNAs (MicroRNA)IBA 01/2018
1	AntigensIBA 01/2018
1	Biomarkers (Surrogate Marker)IBA 03/2016
1	Cyclic AMP Response Element-Binding Protein (Cyclic AMP-Responsive DNA-Binding Protein)IBA 12/2013
1	Olanzapine (Zyprexa)FDA Link 11/2012
1	Synapsins (Synapsin I)IBA 01/2012
1	Quetiapine Fumarate (Seroquel)FDA Link 02/2009
1	Anti-Anxiety Agents (Anxiolytics)IBA 01/2009
1	Proteins (Proteins, Gene)FDA Link 09/2008
1	Brain-Derived Neurotrophic Factor (BDNF)IBA 09/2008
1	Biological ProductsIBA 06/2008
1	Complement System Proteins (Complement)IBA 10/2006

Therapy/Procedure

3	Therapeutics 11/2021 - 01/2010
2	Polypharmacy 05/2018 - 01/2005
1	Bed Rest (Bedrest) 04/2006